Aim­mune en­ters in­to loan agree­ment with KKR; Boehringer bags rights to sec­ond RNAi drug from Dicer­na

→ Hav­ing sub­mit­ted its FDA ap­pli­ca­tion to mar­ket its peanut al­ler­gy drug in De­cem­ber — in ef­fect leapfrog­ging ri­val DBV Tech­nolo­gies $DB­VT — Aim­mune Ther­a­peu­tics $AIMT has en­tered in­to a $170 mil­lion loan agree­ment with in­vest­ment firm KKR.

*sigh* When will biotech's ever learn? Don't is­sue debt un­less you are al­ready prof­itable. Things can go wrong. $SGYP is a great re­cent ex­am­ple of this, an FDA ap­proved prod­uct that is sell­ing (though less than ex­pect­ed) but they're still go­ing bank­rupt be­cause of debt. $AIMT https://t.co/lO3gl­h­Fa1x

— Max­im Ja­cobs, CFA (@Max­Ja­cob­sEdi­son) Jan­u­ary 4, 2019

→ Ger­many’s Boehringer In­gel­heim has picked up rights to a sec­ond RNAi pro­gram from Dicer­na. the pact is cen­tered in find­ing new drugs for NASH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER